Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).

TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.

An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.

TissueCypher stratified BE patients with a community-based diagnosis of LGD with diagnostic accuracy comparable to three renowned expert pathologists.

TissueCypher provided superior risk stratification that outperformed crypt atypia scores.

To determine how results from a prognostic 40-gene expression profiling (40-GEP) test would impact clinician management decisions and how their choices would align with a National Comprehensive Cancer Network (NCCN) compliant, risk-directed management plan for high-risk cutaneous squamous cell carcinoma (cSCC).

To integrate gene expression profiling into the management of high-risk cutaneous squamous cell carcinoma (cSCC) within the National Comprehensive Cancer Network (NCCN) guidelines to improve risk-aligned management recommendations.

Patients managed in accordance with a benign 23-GEP result, including forgoing re-excision, reported no adverse events during the follow-up period

TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.

Survey and clinical vingettes to determine the impact of three factors - Breslow thickness, ulceration, and sentinel lymph node biopsy status - on the decision to order the 31-GEP test.

Comparison and accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool

Risk appropriate management recommendations for implementing SLNB and imaging were more likely to be made following incorporation of DecisionDx-Melanoma test results.